Skip to main content
SpringerLink
Log in
Birkhäuser

Pulmonary Actions of the Endothelins

  • Book
  • © 1998

Overview

Editors:
  1. Roy G. Goldie

    1. Faculty of Medicine & Dentistry Department of Pharmacology, University of Western Australia, Perth Nedlands, Australia

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  2. Douglas W. P. Hay

    1. Department of Pulmonary Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

Part of the book series: Respiratory Pharmacology and Pharmacotherapy (RPP)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (13 chapters)

  1. Front Matter

    Pages i-x
    Download chapter PDF

  2. History of Endothelin

    • Katsutoshi Goto
    Pages 1-20

  3. Endothelin Receptors and Ligands

    • Timothy D. Warner
    Pages 21-48

  4. Cellular Localization of the Endothelin System in the Lung

    • Nicholas W. Morrell, Carlos Orte, John Wharton, Julia M. Polak
    Pages 49-62

  5. Activity and Distribution of the Endothelin-Converting Enzyme in the Lung

    • Pedro D’OrlĂ©ans-Juste, Jean-Philippe Gratton, Ghassan Bkaily, Adel Giaid
    Pages 63-82

  6. ET Receptor-Linked Signal Transduction Processes in the Airway Wall

    • Peter J. Henry
    Pages 83-106

  7. In Vitro Effects of the Endothelins on Airway and Vascular Smooth Muscle Tone

    • Claude Bertrand, Emmanuel Naline, Charles Advenier
    Pages 107-123

  8. In Vivo Effects of Endothelins in the Lung

    • William M. Abraham
    Pages 125-141

  9. Endothelin in Lung Development and Tissue Growth

    • Vera P. Krymskaya, Reynold A. Panettieri Jr
    Pages 143-154

  10. Endothelin and the Airway Epithelium

    • Joaquim Mullol, James N. Baraniuk, Cesar Picado, James H. Shelhamer
    Pages 155-176

  11. Endothelin as a Proinflammatory Mediator

    • János G. Filep, Douglas W. P. Hay
    Pages 177-196

  12. Endothelin-Induced Neuromodulation

    • Karen O. McKay
    Pages 197-211

  13. Role of Endothelin in Pulmonary Hypertension

    • Bernadette Raffestin, Saadia Eddahibi, Serge Adnot
    Pages 213-230

  14. Endothelin as a Putative Mediator in Asthma and Other Respiratory Diseases

    • Anthony E. Redington
    Pages 231-263

  15. Back Matter

    Pages 265-270
    Download chapter PDF
Back to top

Keywords

About this book

The biology of the family of endogenous autocrine peptides known as the endothelins (ETs) has been a source of intense study for researchers since 1988, following the identification of ET-l as the previously described endothelium-derived contractile factor. Initial interest focussed on the actions of the ETs in the cardiovascular system, and this remains the pri­ mary source of published work involving these peptides. Importantly, evi­ dence is mounting for a significant mediator role for ET-l in cardiovascu­ lar diseases including systemic hypertension and congestive heart failure. However, it was also recognized early on that the ETs exert an array of powerful actions in the respiratory tract, many of which prompted specula­ tion concerning mediator roles for ET-l in several lung diseases including asthma and pulmonary hypertension. In recent years the evidence for the involvement of ET-l in lung diseases has become more compelling. There is now real hope and anticipation that novel ET receptor antagonists may eventually be used therapeutically against asthma and other major lung pathologies. It is this atmosphere of excitement created by new discoveries and the increasing scientific ratio­ nale for a significant impact ofthe ETs in pulmonary diseases that prompt­ ed the creation of this book, the first on this topic. Most of the information presented relates to ET-l, which is the most widely studied member of the ET family.

Editors and Affiliations

  • Faculty of Medicine & Dentistry Department of Pharmacology, University of Western Australia, Perth Nedlands, Australia

    Roy G. Goldie

  • Department of Pulmonary Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, USA

    Douglas W. P. Hay

Bibliographic Information

Publish with us

Policies and ethics

Back to top

Search

Navigation